About Deutsches Krebsforschungszentrum

Cancer, with over 450,000 new cases diagnosed and 270,000 deaths each year, is one of the most dreaded diseases and the second most frequent cause of death in Germany. More than almost any other disease, cancer poses tremendous challenges for research and clinical practice. Practically every organ can be affected, every type of cancer has its own rules, and the underlying changes in affected cells are extremely complex. In order to develop novel, more effective methods of diagnosis and treatment, we first need to understand the basic mechanisms of cancer. In recent years, researchers at the German Cancer Research Center in Heidelberg have achieved major advances both in basic research and in the development of novel methods for clinical application. This has received special recognition in 2008, when Professor Harald zur Hausen was awarded the Nobel Prize for Medicine for his outstanding scientific contribution to the study of human papillomaviruses (HPV).

Facts about Deutsches Krebsforschungszentrum
  • Employees: 1001-5,000
  • Industry : Diagnostics

Product portfolio of Deutsches Krebsforschungszentrum

Product portfolio

Here you will find Deutsches Krebsforschungszentrum - DKFZ

Last viewed contents

“And the Science Awards go to…” - Bayer Foundation announces Science Awards winners of 2024

“And the Science Awards go to…” - Bayer Foundation announces Science Awards winners of 2024

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success

VTU Group appoints Liam O'Neil as new CEO

VTU Group appoints Liam O'Neil as new CEO

Dr. Wolf-Henning Walther becomes new CEO at Metrohm Germany - Change in the Executive Board from September 1, 2025

Dr. Wolf-Henning Walther becomes new CEO at Metrohm Germany - Change in the Executive Board from September 1, 2025

Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector

Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector

Pioneers of epigenetics receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2026 - The prizewinners' discovery shook the foundations of classical genetics and opened the door to the vast field of modern epigenetics

Pioneers of epigenetics receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2026 - The prizewinners' discovery shook the foundations of classical genetics and opened the door to the vast field of modern epigenetics

Melina Schuh honored with Science Breakthrough 2025 - “It has always been my dream to make the entire ovulation process visible”

Melina Schuh honored with Science Breakthrough 2025 - “It has always been my dream to make the entire ovulation process visible”

Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026

Kai Beckmann to Succeed Belén Garijo as Chair of the Executive Board and CEO of Merck as of May 2026

Change of managing directors at 5-HT Chemistry & Health - Innovation partner for companies in the chemical, pharmaceutical, and healthcare industries under new management

Change of managing directors at 5-HT Chemistry & Health - Innovation partner for companies in the chemical, pharmaceutical, and healthcare industries under new management

Boehringer Ingelheim Pharma GmbH & Co. KG - Ingelheim am Rhein, Germany

Boehringer Ingelheim Pharma GmbH & Co. KG - Ingelheim am Rhein, Germany

Herz- und Diabeteszentrum Nordrhein-Westfalen (Universitätsklinik der Ruhr-Universität Bochum) - Bad Oeynhausen, Germany

Lead Discovery Center GmbH - Dortmund, Germany

Lead Discovery Center GmbH - Dortmund, Germany